SUPERNUS PHARMACEUTICALS, INC. (SUPN): debt financing — Supernus borrows $93M under credit line, repays $402.5M convertible notes due 2023

SUPERNUS PHARMACEUTICALS, INC.

Borrowed $93M from UBS Bank USA on March 30, 2023 under a $150M revolving credit line.
Used proceeds plus available cash to repay the full $402.5M principal and $1.3M interest on its 0.625% Convertible Senior Notes due April 2023.
Credit line is secured by company accounts, securities, and investment property held at UBS.
Following repayment, the 2023 Notes are no longer outstanding.

item 2.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

SUPERNUS PHARMACEUTICALS, INC. incurred credit facility of $93 million with UBS Bank USA at variable rate.

Instrument: credit facility
Principal: $93 million
Counterparty: UBS Bank USA
Rate: variable rate
Event: incurrence

Exact text from the filing

On March 30, 2023 the Company borrowed $93 million pursuant to the credit line agreement with UBS Bank USA ("UBS") dated as of February 8, 2023 (the "Credit Line").

View on SEC.gov

Browse all debt financings →

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001356576-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.